WEST Search History

DATE: Friday, March 07, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L6	L5 not l3	2	L6
L5	(L3 or l2) and mutat$	13	L5
L4	L3 and l2	15	L4
L3	factor vii activating and (protease or proteolytic)	27	L3
L2	factor vii adj2 activ$ near3 (protease or proteolytic)	21	L2
L1	factor vii adj2 activ$ near3 prote$	33	L1

END OF SEARCH HISTORY

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 27 returned.

1. Document ID: US 20020142316 A1

L3: Entry 1 of 27 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142316
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020142316 A1

TITLE: Mutants of the factor VII-activating protease and detection methods using specific antibodies

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roemisch, Juergen	Marburg		DE	
Stoehr, Hans-Arnold	Wetter		DE	
Feussner, Annette	Marburg		DE	
Lang, Wiegand	Colbe		DE	
Weimer, Thomas	Gladenbach		DE	
Becker, Margret	Marburg		DE	
Nerlich, Claudia	Marburg		DE	
Muth-Naumann, Gudrun	Wetter		DE	

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

2. Document ID: US 20020119153 A1

L3: Entry 2 of 27 File: PGPB Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119153
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020119153 A1

TITLE: Antibody conjugate formulations for selectively inhibiting VEGF

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Thorpe, Philip E.	Dallas	TX	US	
Brekken, Rolf A.	Seattle	WA	US	

US-CL-CURRENT: 424/145.1; 424/133.1, 530/388.24

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

3. Document ID: US 20020110552 A1

L3: Entry 3 of 27 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110552
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020110552 A1

TITLE: Stabilized liquid preparation of the protease which activates blood coagulation factor VII, or of its proenzyme

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Romisch, Jurgen	Marburg		DE	
Feussner, Annette	Marburg		DE	
Kannemeier, Christian	Marburg		DE	
Stohr, Hans-Arnold	Wetter		DE	

US-CL-CURRENT: 424/94.63

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

4. Document ID: US 20020061850 A1

L3: Entry 4 of 27 File: PGPB May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061850
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061850 A1

TITLE: Regulation of human transmembrane serine protease

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xiao, Yonghong	Cambridge	MA	US	
Gedrich, Richard W.	Guilford	CT	US	

US-CL-CURRENT: 514/12; 435/183, 435/320.1, 435/325, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

5. Document ID: US 6528299 B1

L3: Entry 5 of 27 File: USPT Mar 4, 2003

US-PAT-NO: 6528299
DOCUMENT-IDENTIFIER: US 6528299 B1

TITLE: Protease for activating clotting factor VII

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

6. Document ID: US 6524583 B1

L3: Entry 6 of 27 File: USPT Feb 25, 2003

US-PAT-NO: 6524583
DOCUMENT-IDENTIFIER: US 6524583 B1

TITLE: Antibody methods for selectively inhibiting VEGF

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

7. Document ID: US 6423543 B1

L3: Entry 7 of 27 File: USPT Jul 23, 2002

US-PAT-NO: 6423543
DOCUMENT-IDENTIFIER: US 6423543 B1

TITLE: Antisense modulation of hepsin expression

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

8. Document ID: US 6416758 B1

L3: Entry 8 of 27 File: USPT Jul 9, 2002

US-PAT-NO: 6416758
DOCUMENT-IDENTIFIER: US 6416758 B1

TITLE: Antibody conjugate kits for selectively inhibiting VEGF

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

9. Document ID: US 6342221 B1

L3: Entry 9 of 27 File: USPT Jan 29, 2002

US-PAT-NO: 6342221
DOCUMENT-IDENTIFIER: US 6342221 B1

TITLE: Antibody conjugate compositions for selectively inhibiting VEGF

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments KWIC | Draw Desc | Image

10. Document ID: US 6342219 B1

L3: Entry 10 of 27 File: USPT Jan 29, 2002

US-PAT-NO: 6342219
DOCUMENT-IDENTIFIER: US 6342219 B1

TITLE: Antibody compositions for selectively inhibiting VEGF

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
factor vii activating and (protease or proteolytic)	27

Display Format: - Change Format

Previous Page Next Page

WEST

Generate Collection | Print

Search Results - Record(s) 11 through 20 of 27 returned.

11. Document ID: US 6312694 B1

L3: Entry 11 of 27 File: USPT Nov 6, 2001

US-PAT-NO: 6312694
DOCUMENT-IDENTIFIER: US 6312694 B1

TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

12. Document ID: US 6160097 A

L3: Entry 12 of 27 File: USPT Dec 12, 2000

US-PAT-NO: 6160097
DOCUMENT-IDENTIFIER: US 6160097 A

TITLE: Process for reactivating purified membrane proteins by freezing them

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

13. Document ID: US 6156321 A

L3: Entry 13 of 27 File: USPT Dec 5, 2000

US-PAT-NO: 6156321
DOCUMENT-IDENTIFIER: US 6156321 A

TITLE: Tissue factor methods and compositions for coagulation and tumor treatment

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

14. Document ID: US 6132730 A

L3: Entry 14 of 27 File: USPT Oct 17, 2000

US-PAT-NO: 6132730
DOCUMENT-IDENTIFIER: US 6132730 A

TITLE: Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

15. Document ID: US 6132729 A

L3: Entry 15 of 27 File: USPT Oct 17, 2000

US-PAT-NO: 6132729
DOCUMENT-IDENTIFIER: US 6132729 A

TITLE: Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

16. Document ID: US 6031081 A

L3: Entry 16 of 27 File: USPT Feb 29, 2000

US-PAT-NO: 6031081
DOCUMENT-IDENTIFIER: US 6031081 A

TITLE: Process for reactivating purified membrane proteins by freezing them

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

17. Document ID: US 5580744 A

L3: Entry 17 of 27 File: USPT Dec 3, 1996

US-PAT-NO: 5580744
DOCUMENT-IDENTIFIER: US 5580744 A

TITLE: Test article and method for performing blood coagulation assays

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

18. Document ID: JP 2002249441 A

L3: Entry 18 of 27 File: JPAB Sep 6, 2002

PUB-NO: JP02002249441A
DOCUMENT-IDENTIFIER: JP 2002249441 A
TITLE: BLOOD COAGULATION FACTOR VII-ACTIVATING-PROTEASE AND STABLE LIQUID PREPARATION CONTAINING PROENZYME THEREOF

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

19. Document ID: JP 2001029098 A

L3: Entry 19 of 27 File: JPAB Feb 6, 2001

PUB-NO: JP02001029098A
DOCUMENT-IDENTIFIER: JP 2001029098 A
TITLE: ACTIVITY MEASUREMENT OF FACTOR VII-ACTIVATING PROTEASE CONTAINED IN PROTEIN SOLUTION

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

20. Document ID: EP 1182258 A1

L3: Entry 20 of 27 File: EPAB Feb 27, 2002

PUB-NO: EP001182258A1
DOCUMENT-IDENTIFIER: EP 1182258 A1
TITLE: Mutants of the factor VII activating protease and methods for their detection

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
factor vii activating and (protease or proteolytic)	27

Display Format: - Change Format

Previous Page Next Page

biological functions, and removal of a tag is not necessarily required prior to use of the TF construct in the present invention.

Detailed Description Text (309):
Two RIBS epitopes have been localized by Ugarova et al. (1993). One sequence resides at .gamma.112-119 and is recognized by MAb 9F9; the second is the RGDF sequence at A.alpha. 95-98 and is recognized by mAb 155B16. These epitopes are also exposed by adsorption of fibrinogen onto a plastic surface and digestion of the molecule by plasmin. Proteolytic exposure of the epitopes coincides with cleavage of the carboxyl-terminal aspects of the A.alpha.-chains to form fragment X.sub.2. The inaccessibility of the RGDF sequence at A.alpha. 95-98 in fibrinogen suggests that this sequence does not participate in the initial binding of the molecule to GPIIb-IIIa.

Detailed Description Text (330):
Depending on the specific toxin compound used as part of the fusion protein, it may be necessary to provide a peptide spacer operatively attaching the targeting agent and the toxin compound which is capable of folding into a disulfide-bonded loop structure. Proteolytic cleavage within the loop would then yield a heterodimeric polypeptide wherein the targeting agent and the toxin compound are linked by only a single disulfide bond. See, for example, Lord et al. (1992). An example of such a toxin is a Ricin A-chain toxin.

Detailed Description Text (331):
When certain other toxin compounds are utilized, a non-cleavable peptide spacer may be provided to operatively attach the targeting agent and the toxin compound of the fusion protein. Toxins which may be used in conjunction with non-cleavable peptide spacers are those which may, themselves, be converted by proteolytic cleavage, into a cytotoxic disulfide-bonded form (see for example, Ogata et al., 1990). An example of such a toxin compound is a Pseudonomas exotoxin compound.

Detailed Description Text (344):
Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

Detailed Description Text (362):
Exemplary tTF prodrugs have the following structures: tTF.sub.1-219 (X).sub.n1 (Y) n.sub.2 Z Ligand, where tTF.sub.1-219 represents TF minus the cytosolic and transmembrane domains; X represents a hydrophobic transmembrane domain n1 amino acids (AA) in length (n=1-20 AA); Y represents a hydrophilic protease recognition sequence of n2 AA in length (sufficient AA to ensure appropriate protease recognition); Z represents a disulfide thioester or other linking group such as (Cys).sub.1-2 ; Ligand represents an antibody or other targeting moiety recognizing tumor-cells, tumor EC, connective tissue (stroma) or basal lamina markers

Detailed Description Text (363):
The tTF prodrug is contemplated for injection intravenously allowing it to localize to diseased tissue (e.g., tumor). Once localized in the diseased tissue, endogenous proteases (e.g., m et alloproteinases, thrombin, Factor Xa, Factor VIIa, Factor IXa, plasmin) will cleave the hydrophilic protease recognition sequence from the prodrug which will allow the hydrophobic transmembrane sequence to insert into a local cell membrane. Once the tail has inserted into the membrane, the tTF will regain its coagulation-inducing properties resulting in clot formation in the vasculature of the diseased tissue.

Detailed Description Text (425):
Fab fragments can be obtained by proteolysis of the whole immunoglobulin by the non-specific thiol protease, papain. Papain must first be activated by reducing the sulphydryl group in the active site with cysteine, 2-mercaptoethanol or dithiothreitol. Heavy m et als in the stock enzyme should be removed by chelation with EDTA (2 mM) to ensure maximum enzyme activity. Enzyme and substrate are normally mixed together in the ratio of 1:100 by weight. After incubation, the reaction can be stopped by irreversible alkylation of the thiol group with iodoacetamide or simply by

dialysis. The completeness of the digestion should be monitored by SDS-PAGE and the various fractions separated by protein A-Sepharose or ion exchange chromatography.

Detailed Description Text (428):
Digestion of rat IgG by pepsin requires conditions including dialysis in 0.1 M acetate buffer, pH 4.5, and then incubation for four hours with 1% w/w pepsin; IgG.sub.1 and IgG.sub.2a digestion is improved if first dialyzed against 0.1 M formate buffer, pH 2.8, at 4.degree. C., for 16 hours followed by acetate buffer. IgG.sub.2 b gives more consistent results with incubation in staphylococcal V8 protease (3% w/w) in 0.1 M sodium phosphate buffer, pH 7.8, for four hours at 37.degree. C.

Other Reference Publication (12):
Morrissey et al., "Molecular cloning of the cDNA for tissue factor, the cellular receptor for initiation of the coagulation protease cascade," Cell 50:129-135, 1987.

Other Reference Publication (24):
Ruf et al., "Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII," J. Biol. Chem. 267(31):22206-22210, 1992.

Other Reference Publication (25):
Ruf et al., "Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex," J. Biol. Chem. 267(9):6375-6381, 1992.

WEST

Generate Collection | Print

L3: Entry 14 of 27 File: USPT Oct 17, 2000

DOCUMENT-IDENTIFIER: US 6132730 A
TITLE: Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Brief Summary Text (12):
In further studies connected with Tissue Factor (TF), Edgington and colleagues have shown that, in contrast to normal melanocytes, malignant metastasizing human melanoma cells express high levels of TF, the major cellular initiator of the plasma coagulation protease cascades (WO 94/28017; WO 94/05328; U.S. Pat. No. 5,437,864). It was reported that inhibition of TF function and subsequent reduction in local protease generation resulted in significantly reduced numbers of tumor cells retained in the vasculature. This led to the suggestion that there was a direct correlation between TF expression and the metastatic phenotype of tumor cells. Edgington and colleagues proposed that a function of TF is required for successful implantation of tumor cells and that interference with TF function, or specific interference with cell surface expression of TF, is useful in inhibiting metastasis. These authors have therefore proposed treating cancer with antibodies directed against Tissue Factor.

Detailed Description Text (11):
263 amino acid membrane glycoprotein (SEQ ID NO:12), and its primary sequence has structural similarity with the chemokine receptor family (Edgington et al., 1991). TF is a transmembrane cell surface receptor and functions as the receptor and cofactor for Factor VIIa. TF binds Factor VIIa to form a proteolytically active complex on the cell surface (Ruf and Edgington, 1991b, 1994; Ruf et al., 1991, 1992a, 1992b). This complex rapidly activates the serine protease zymogens Factors IX and X by limited proteolysis, leading to the formation of thrombin and, ultimately, a blood clot (FIG. 21).

Detailed Description Text (62):
this region may also prove to be relevant to the Factor VII activating activity, and one may therefore consider introducing mutations into any one or more of the residues generally located between about amino acid 106 and about amino acid 209 of the TF sequence (WO 94/07515). In terms of the preferred region, one may generally consider mutating any one or more of amino acids 147, 152, 154, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 and/or 167. With reference to the generally preferred candidate mutations outside this region, one may refer to the following amino acid substitutions: S16, T17, S39, T30, S32, D34, V67, L104, B105, T106, R131, R136, V145, V146, F147, V198, N199, R200 and K201, with amino acids A34, E34 and R34 also being considered (WO 94/28017).

Detailed Description Text (143):
As disclosed herein in detail, the generally preferred techniques for purifying expressed TF constructs for use in the present invention involve the generation of a TF molecule that includes an affinity purification tag and the use of an affinity separation matrix for obtaining the TF construct free from most or all contaminating species. Many such fusion protein tags are known to those of ordinary skill in the art and such expression and separating protocols can be easily executed. Technology is also available for cleaving the original affinity tag prior to use of the released protein or polypeptide, which may be effected by inserting a protease-sensitive linker between the affinity tag and the protein of interest. Such methodology is indeed employed in connection with aspects of the present invention. U.S. Pat. No. 5,298,599 is also instructive in this regard. However, it is also known that many such tags do not impair the ability of the expressed protein to carry out their

biological functions, and removal of a tag is not necessarily required prior to use of the TF construct in the present invention.

Detailed Description Text (309):
Two RIBS epitopes have been localized by Ugarova et al. (1993). One sequence resides at .gamma.112-119 and is recognized by MAb 9F9; the second is the RGDF sequence at A.alpha. 95-98 and is recognized by mAb 155B16. These epitopes are also exposed by adsorption of fibrinogen onto a plastic surface and digestion of the molecule by plasmin. Proteolytic exposure of the epitopes coincides with cleavage of the carboxyl-terminal aspects of the A.alpha.-chains to form fragment X.sub.2. The inaccessibility of the RGDF sequence at A.alpha. 95-98 in fibrinogen suggests that this sequence does not participate in the initial binding of the molecule to GPIIb-IIIa.

Detailed Description Text (330):
Depending on the specific toxin compound used as part of the fusion protein, it may be necessary to provide a peptide spacer operatively attaching the targeting agent and the toxin compound which is capable of folding into a disulfide-bonded loop structure. Proteolytic cleavage within the loop would then yield a heterodimeric polypeptide wherein the targeting agent and the toxin compound are linked by only a single disulfide bond. See, for example, Lord et al. (1992). An example of such a toxin is a Ricin A-chain toxin.

Detailed Description Text (331):
When certain other toxin compounds are utilized, a non-cleavable peptide spacer may be provided to operatively attach the targeting agent and the toxin compound of the fusion protein. Toxins which may be used in conjunction with non-cleavable peptide spacers are those which may, themselves, be converted by proteolytic cleavage, into a cytotoxic disulfide-bonded form (see for example, Ogata et al., 1990). An example of such a toxin compound is a Pseudonomas exotoxin compound.

Detailed Description Text (344):
Russell's viper venom was shown to contain a coagulant protein by Williams and Esnouf in 1962. Kisiel (1979) isolated a venom glycoprotein that activates Factor V; and Di Scipio et al. (1977) showed that a protease from the venom activates human Factor X. The Factor X activator is the component contemplated for use in this invention.

Detailed Description Text (362):
Exemplary tTF prodrugs have the following structures: tTF.sub.1-219 (X).sub.n1 (Y) n.sub.2 Z Ligand, where tTF.sub.1-219 represents TF minus the cytosolic and transmembrane domains; X represents a hydrophobic transmembrane domain n1 amino acids (AA) in length (n=1-20 AA); Y represents a hydrophilic protease recognition sequence of n2 AA in length (sufficient AA to ensure appropriate protease recognition); Z represents a disulfide thioester or other linking group such as (Cys).sub.1-2 ; Ligand represents an antibody or other targeting moiety recognizing tumor-cells, tumor EC, connective tissue (stroma) or basal lamina markers

Detailed Description Text (363):
The tTF prodrug is contemplated for injection intravenously allowing it to localize to diseased tissue (e.g., tumor). Once localized in the diseased tissue, endogenous proteases (e.g., m et alloproteinases, thrombin, Factor Xa, Factor VIIa, Factor IXa, plasmin) will cleave the hydrophilic protease recognition sequence from the prodrug which will allow the hydrophobic transmembrane sequence to insert into a local cell membrane. Once the tail has inserted into the membrane, the tTF will regain its coagulation-inducing properties resulting in clot formation in the vasculature of the diseased tissue.

Detailed Description Text (425):
Fab fragments can be obtained by proteolysis of the whole immunoglobulin by the non-specific thiol protease, papain. Papain must first be activated by reducing the sulphydryl group in the active site with cysteine, 2-mercaptoethanol or dithiothreitol. Heavy m et als in the stock enzyme should be removed by chelation with EDTA (2 mM) to ensure maximum enzyme activity. Enzyme and substrate are normally mixed together in the ratio of 1:100 by weight. After incubation, the reaction can be stopped by irreversible alkylation of the thiol group with iodoacetamide or simply by

dialysis. The completeness of the digestion should be monitored by SDS-PAGE and the various fractions separated by protein A-Sepharose or ion exchange chromatography.

Detailed Description Text (428):
Digestion of rat IgG by pepsin requires conditions including dialysis in 0.1 M acetate buffer, pH 4.5, and then incubation for four hours with 1% w/w pepsin; IgG.sub.1 and IgG.sub.2a digestion is improved if first dialyzed against 0.1 M formate buffer, pH 2.8, at 4.degree. C., for 16 hours followed by acetate buffer. IgG.sub.2 b gives more consistent results with incubation in staphylococcal V8 protease (3% w/w) in 0.1 M sodium phosphate buffer, pH 7.8, for four hours at 37.degree. C.

Other Reference Publication (12):
Morrissey et al., "Molecular cloning of the cDNA for tissue factor, the cellular receptor for initiation of the coagulation protease cascade," Cell 50:129-135, 1987.

Other Reference Publication (24):
Ruf et al., "Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII," J. Biol. Chem. 267(31):22206-22210, 1992.

Other Reference Publication (25):
Ruf et al., "Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex," J. Biol. Chem. 267(9):6375-6381, 1992.

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 2 of 2 returned.

1. Document ID: US 6320029 B1

L6: Entry 1 of 2 File: USPT Nov 20, 2001

US-PAT-NO: 6320029
DOCUMENT-IDENTIFIER: US 6320029 B1

TITLE: Methods of production and use of liquid formulations of plasma proteins

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

2. Document ID: US 5925738 A

L6: Entry 2 of 2 File: USPT Jul 20, 1999

US-PAT-NO: 5925738
DOCUMENT-IDENTIFIER: US 5925738 A

TITLE: Methods of production and use of liquid formulations of plasma proteins

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

Generate Collection | Print

Terms	Documents
L5 not l3	2

Display Format: - Change Format

Previous Page Next Page

```
 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0JB(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 19:43:17 ON 07 MAR 2003

=> fil .eliz
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 19:43:26 ON 07 MAR 2003

FILE 'SCISEARCH' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'BIOTECHDS' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'HCAPLUS' ENTERED AT 19:43:26 ON 07 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 19:43:26 ON 07 MAR 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'ESBIOBASE' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 19:43:26 ON 07 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s factor vii activating and (protease or proteolytic)
   4 FILES SEARCHED...
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 43	Feb 13	CANCERLIT is no longer being updated
NEWS 44	Feb 24	METADEX enhancements
NEWS 45	Feb 24	PCTGEN now available on STN
NEWS 46	Feb 24	TEMA now available on STN
NEWS 47	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 48	Feb 26	PCTFULL now contains images
NEWS 49	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results

L1 59 FACTOR VII ACTIV ING AND (PROTEASE OR PROTEOLYTIC

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 24 DUP REM L1 (35 DUPLICATES REMOVED)

=> d 1-10

L2 ANSWER 1 OF 24 MEDLINE
AN 2003068564 MEDLINE
DN 22466630 PubMed ID: 12578860
TI **Factor VII-activating protease**:
coagulation, fibrinolysis, and atherothrombosis?.
CM Comment on: Circulation. 2003 Feb 11;107(5):667-70
AU Mann Kenneth G
NC HL-46703 (NHLBI)
SO CIRCULATION, (2003 Feb 11) 107 (5) 654-5.
Journal code: 0147763. ISSN: 1524-4539.
CY United States
DT Commentary
Editorial
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200302
ED Entered STN: 20030212
Last Updated on STN: 20030227
Entered Medline: 20030226

L2 ANSWER 2 OF 24 MEDLINE DUPLICATE 1
AN 2003068568 MEDLINE
DN 22466634 PubMed ID: 12578864
TI Marburg I polymorphism of **factor VII**--
activating protease: a prominent risk predictor of
carotid stenosis.
CM Comment in: Circulation. 2003 Feb 11;107(5):654-5
AU Willeit Johann; Kiechl Stefan; Weimer Thomas; Mair Artur; Santer Peter;
Wiedermann Christian J; Roemisch Juergen
CS Department of Neurology, University Clinics, Innsbruck, Austria..
johann.willeit@uibk.ac.at
SO CIRCULATION, (2003 Feb 11) 107 (5) 667-70.
Journal code: 0147763. ISSN: 1524-4539.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200302
ED Entered STN: 20030212
Last Updated on STN: 20030227
Entered Medline: 20030226

L2 ANSWER 3 OF 24 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2003081620 EMBASE
TI **Factor VII-activating protease**:
Coagulation, fibrinolysis, and atherothrombosis?.
AU Mann K.G.
CS Dr. K.G. Mann, University of Vermont, Department of Biochemistry, C-401
Given Building, 89 Beaumont Avenue, Burlington, VT 05405-0068, United
States. kenneth.mann@uvm.edu
SO Circulation, (11 Feb 2003) 107/5 (654-655).
Refs: 18
ISSN: 0009-7322 CODEN: CIRCAZ
CY United States
DT Journal; Editorial
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
LA English

L2 ANSWER 4 OF 24 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
AN 2002:517916 HCAPLUS

DN 137:83616
TI Stabilized liquid drug delivery system containing blood-coagulation **factor VII-activating protease** or its proenzyme
IN Roemisch, Juergen; Stoehr, Hans-Arnold
PA Aventis Behring Gmbh, Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10131404	A1	20020711	DE 2001-10131404	20010625
	EP 1226829	A2	20020731	EP 2001-129605	20011212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002110552	A1	20020815	US 2002-33777	20020103
	AU 2002010069	A5	20020711	AU 2002-10069	20020107
	JP 2002249441	A2	20020906	JP 2002-316	20020107
PRAI	DE 2001-10100483	IA	20010108		
	DE 2001-10131404	A	20010625		

L2 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:157176 HCAPLUS
DN 136:197598
TI Alleles of the human **factor VII activating protease** gene and their detection
IN Roemisch, Juergen; Stoehr, Hans-arnold; Feussner, Annette; Lang, Wiegand; Weimer, Thomas; Becker, Margret; Nerlich, Claudia; Muth-Naumann, Gudrun
PA Aventis Behring Gmbh, Germany
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1182258	A1	20020227	EP 2001-115691	20010705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10036641	A1	20020214	DE 2000-10036641	20000726
	DE 10052319	A1	20020411	DE 2000-10052319	20001021
	DE 10118706	A1	20021017	DE 2001-10118706	20010412
PRAI	DE 2000-10036641	A	20000726		
	DE 2000-10050040	A	20001010		
	DE 2000-10052319	A	20001021		
	DE 2001-10118706	A	20010412		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:122504 HCAPLUS
DN 136:147482
TI Preparation and usage of monoclonal antibodies to blood-coagulation **factor VII-activating protease** (FSAP)
IN Roemisch, Juergen; Feussner, Annette; Stoehr, Hans-Arnold; Lang, Wiegand
PA Aventis Behring G.m.b.H., Germany
SO Ger. Offen., 4 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10036641	A1	20020214	DE 2000-10036641	20000726
	EP 1182258	A1	20020227	EP 2001-115691	20010705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

PI JP 2002291486 A2 20021008 JP 2001-224423 20010725
US 2002142316 A1 20021003 US 2001-912559 20010726
PRAI DE 2000-10036641 A 20000726
DE 2000-10050040 A 20001010
DE 2000-10052319 A 20001021
DE 2001-10118706 A 20010412
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 24 MEDLINE DUPLICATE 3
AN 2002676486 IN-PROCESS
DN 22324062 PubMed ID: 12437095
TI **Factor VII activating protease** (FSAP): a novel **protease** in hemostasis.
AU Romisch Jugrgen
CS Aventis Behring GmbH, Research, Marburg, Germany.
SO BIOLOGICAL CHEMISTRY, (2002 Jul-Aug) 383 (7-8) 1119-24.
Journal code: 9700112. ISSN: 1431-6730.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20021120
Last Updated on STN: 20021212

L2 ANSWER 8 OF 24 MEDLINE DUPLICATE 4
AN 2002389182 MEDLINE
DN 22133046 PubMed ID: 12138371
TI The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the **factor VII activating protease** (FSAP).
AU Roemisch J; Feussner A; Nerlich C; Stoehr H-A; Weimer T
CS Aventis Behring GmbH, Preclinical Research & Development, Marburg, Germany.. Juergen.Roemisch@aventis.com
SO BLOOD COAGULATION AND FIBRINOLYSIS, (2002 Jul) 13 (5) 433-41.
Journal code: 9102551. ISSN: 0957-5235.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 20020725
Last Updated on STN: 20030202
Entered Medline: 20030131

L2 ANSWER 9 OF 24 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2001-07582 BIOTECHDS
TI Purification of **factor-VII activating protease**, useful for treating blood clotting disorders, comprises performing anion- and/or cation-exchange chromatography at a pH below the isoelectric point;
downstream processing
AU Roemisch J; Feussner A; Stoehr H A
PA Aventis-Behring
LO Marburg, Germany.
PI EP 1074616 7 Feb 2001
AI EP 2000-114370 5 Jul 2000
PRAI DE 1999-1037219 6 Aug 1999
DT Patent
LA German
OS WPI: 2001-184356 [19]

L2 ANSWER 10 OF 24 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2001-07581 BIOTECHDS
TI Purifying **Factor-VII-activating protease** or its precursor, useful for promoting coagulation, comprises performing fractional precipitation or affinity chromatography;
recombinant protein purification and transgenic animal for downstream

processing and coagula[redacted]n deficiency, thrombosis disea[redacted]herapy and vulnerary activity
AU Roemisch J; Feussner A; Stoehr H A
PA Aventis
LO Marburg, Germany.
PI EP 1074615 7 Feb 2001
AI EP 2000-114348 5 Jul 2000
PRAI DE 1999-1037218 6 Aug 1999
DT Patent
LA German
OS WPI: 2001-184355 [19]

=> d 11-20

L2 ANSWER 11 OF 24 MEDLINE DUPLICATE 7
AN 2001376590 MEDLINE
DN 21325956 PubMed ID: 11432747
TI Factor VII and single-chain plasminogen activator-activating **protease**: activation and autoactivation of the proenzyme.
AU Kannemeier C; Feussner A; Stohr H A; Weisse J; Preissner K T; Romisch J
CS Aventis Behring GmbH, Research, Marburg, Germany.
SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (2001 Jul) 268 (13) 3789-96.
Journal code: 0107600. ISSN: 0014-2956.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200109
ED Entered STN: 20010917
Last Updated on STN: 20010917
Entered Medline: 20010913

L2 ANSWER 12 OF 24 MEDLINE
AN 2001458807 MEDLINE
DN 21395892 PubMed ID: 11505081
TI Quantitation of the factor VII- and single-chain plasminogen activator-activating **protease** in plasmas of healthy subjects.
AU Romisch J; Feussner A; Stohr H A
CS Aventis Behring GmbH, Research, Marburg, Germany..
Juergen.Roemisch@aventis.com
SO BLOOD COAGULATION AND FIBRINOLYSIS, (2001 Jul) 12 (5) 375-83.
Journal code: 9102551. ISSN: 0957-5235.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200207
ED Entered STN: 20010816
Last Updated on STN: 20020703
Entered Medline: 20020702

L2 ANSWER 13 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2001:207026 BIOSIS
DN PREV200100207026
TI The prourokinase activating potency of the FVII- and single chain plasminogen activator-activating **protease** (FSAP) is significantly reduced in up to 10% of healthy subjects.
AU Roemisch, J. (1); Feussner, A. (1); Stoehr, H. A. (1)
CS (1) Research, Aventis Behring GmbH, Marburg Germany
SO Annals of Hematology, (2001) Vol. 80, No. Supplement 1, pp. A57. print.
Meeting Info.: 45th Annual Meeting of the Society for Thrombosis/Hemostasis Research Duesseldorf, Germany February 14-17, 2001
ISSN: 0939-5555.
DT Conference
LA English
SL English

L2 ANSWER 14 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2001:196164 BIOSIS
DN PREV200100196164
TI Activators of the FVII- and single chain urokinase plasminogen activator-activating **protease** (FSAP.
AU Kannemeier, C. (1); Feussner, A. (1); Stoehr, H. A. (1); Preissner, K. T.; Roemisch, J. (1)
CS (1) Research, Aventis Behring GmbH, Marburg Germany
SO Annals of Hematology, (2001) Vol. 80, No. Supplement 1, pp. A32. print.
Meeting Info.: 45th Annual Meeting of the Society for Thrombosis/Hemostasis Research Duesseldorf, Germany February 14-17, 2001
ISSN: 0939-5555.
DT Conference
LA English
SL English

L2 ANSWER 15 OF 24 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 8
AN 2000:876807 HCAPLUS
DN 134:26944
TI Method for the determination of blood coagulation factor VII activator in protein solutions using antibodies and applications for blood analysis of heart patients and pregnant woman
IN Romisch, Jurgen; Feussner, Annette; Stohr, Hans-Arnold
PA Aventis Behring G.m.b.H., Germany
SO Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1059359	A2	20001213	EP 2000-111738	20000602
	EP 1059359	A3	20020814		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 10023923	A1	20001214	DE 2000-10023923	20000517
	CA 2311479	AA	20001210	CA 2000-2311479	20000612
	JP 2001029098	A2	20010206	JP 2000-174893	20000612
PRAI	DE 1999-19926531	A	19990610		
	DE 2000-10023923	A	20000517		

L2 ANSWER 16 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2001:95286 BIOSIS
DN PREV200100095286
TI Purification of the proenzyme form of the FVII-activator/sc-PA-activating **protease** and its quantification in plasmas of healthy subjects.
AU Roemisch, J. (1); Kannemeier, C. (1); Feussner, A. (1); Stoehr, H. A. (1); Preissner, K. T.
CS (1) Research, Aventis Behring GmbH, Marburg Germany
SO Journal of Submicroscopic Cytology and Pathology, (July, 2000) Vol. 32, No. 3, pp. 388. print.
Meeting Info.: XIth International Vascular Biology Meeting Geneva, Switzerland September 05-09, 2000
ISSN: 1122-9497.
DT Conference
LA English
SL English

L2 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:690869 HCAPLUS
DN 131:309276
TI **Protease** for activating clotting factor VII and its therapeutical applications
IN Romisch, Jurgen; Stohr, Hans-Arnold; Feussner, Annette
PA Centeon Pharma G.m.b.H., Germany
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DAT[redacted]	APPLICATION NO.	DATE [redacted]
PI	EP 952215	A2	19991027	EP 1999-106913	19990408
	EP 952215	A3	20020626		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	DE 19903693	A1	19991028	DE 1999-19903693	19990320
	US 6528299	B1	20030304	US 1999-295316	19990421
	AU 9923935	A1	19991104	AU 1999-23935	19990423
	AU 748221	B2	20020530		
	JP 2000023696	A2	20000125	JP 1999-116411	19990423
PRAI	DE 1998-19818495	A	19980424		
	DE 1998-19827734	A	19980622		
	DE 1998-19851332	A	19981106		
	DE 1998-19851335	A	19981106		
	DE 1998-19851336	A	19981106		
	DE 1999-19903693	A	19990320		

L2 ANSWER 18 OF 24 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2000:256363 SCISEARCH
GA The Genuine Article (R) Number: 290FP
TI A new **factor VII activating protease** isolated from human plasma
AU Romisch J (Reprint); Feussner A; Vermohlen S; Stohr H A
CS CENTEON PHARMA GMBH, RES, MARBURG, GERMANY
CYA GERMANY
SO THROMBOSIS AND HAEMOSTASIS, (AUG 1999) Supp. [S], pp. 1320-1320. Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 43, LENZHALDE 3, D-70040 STUTTGART, GERMANY.
ISSN: 0340-6245.
DT Conference; Journal
FS LIFE
LA English
REC Reference Count: 0

L2 ANSWER 19 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 2000:274991 BIOSIS
DN PREV200000274991
TI The FVII activating **protease** cleaves single-chain plasminogen activators.
AU Roemisch, Juergen (1); Vermoehlen, Sylvia; Feussner, Annette; Stoehr, Hans-Arnold
CS (1) Aventis Behring GmbH, Research, D-35002, Marburg Germany
SO Haemostasis, (March, 1999(2000)) Vol. 29, No. 5, pp. 292-299. print..
ISSN: 0301-0147.
DT Article
LA English
SL English

L2 ANSWER 20 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1999:211822 BIOSIS
DN PREV199900211822
TI The FVII activating **protease** mediates fibrinolytic effects activating single-chain plasminogen activators.
AU Roemisch, J. (1); Feussner, A. (1); Stoehr, H.-A. (1)
CS (1) Research, Centeon Pharma GmbH, Marburg Germany
SO Annals of Hematology, (1999) Vol. 78, No. SUPPL. 1, pp. A24. Meeting Info.: 43rd Annual Meeting of the Society for Thrombosis and Hemostasis Mannheim, Germany February 24-27, 1999 Society for Thrombosis and Hemostasis
. ISSN: 0939-5555.
DT Conference
LA English

=> d 21-24

L2 ANSWER 21 OF 24 MEDLINE DUPLICATE 9
AN 1998228168 MEDLINE

DN 98228168 PubMed ID: 9569[redacted]
TI Expression of the **factor VII activating protease**, hepsin, in situ in renal cell carcinoma.
AU Zacharski L R; Ornstein D L; Memoli V A; Rousseau S M; Kisiel W
NC HL35246 (NHLBI)
SO THROMBOSIS AND HAEMOSTASIS, (1998 Apr) 79 (4) 876-7.
Journal code: 7608063. ISSN: 0340-6245.
CY GERMANY: Germany, Federal Republic of
DT Letter
LA English
FS Priority Journals
EM 199807
ED Entered STN: 19980723
Last Updated on STN: 20000303
Entered Medline: 19980713

L2 ANSWER 22 OF 24 SCISEARCH COPYRIGHT 2003 ISI (R) DUPLICATE 10
AN 1998:295582 SCISEARCH
GA The Genuine Article (R) Number: ZG420
TI Expression of the **factor VII activating protease**, hepsin, in situ in renal cell carcinoma
AU Zacharski L R (Reprint); Ornstein D L; Memoli V A; Rousseau S M; Kisiel W
CS VA MED & REG OFF CTR, WHITE RIVER JCT, VT 05009 (Reprint); DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MED, HANOVER, NH 03756; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT PATHOL, HANOVER, NH 03756; UNIV NEW MEXICO, SCH MED, DEPT PATHOL, ALBUQUERQUE, NM 87131
CYA USA
SO THROMBOSIS AND HAEMOSTASIS, (APR 1998) Vol. 79, No. 4, pp. 876-877.
Publisher: F K SCHATTAUER VERLAG GMBH, P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY.
ISSN: 0340-6245.
DT Letter; Journal
FS LIFE
LA English
REC Reference Count: 16

L2 ANSWER 23 OF 24 MEDLINE DUPLICATE 11
AN 95113879 MEDLINE
DN 95113879 PubMed ID: 7814421
TI Hepsin, a putative membrane-associated serine **protease**, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation.
AU Kazama Y; Hamamoto T; Foster D C; Kisiel W
CS Department of Pathology, University of New Mexico School of Medicine, Albuquerque 87131.
NC HL35246 (NHLBI)
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1995 Jan 6) 270 (1) 66-72.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199502
ED Entered STN: 19950217
Last Updated on STN: 20000303
Entered Medline: 19950203

L2 ANSWER 24 OF 24 HCAPLUS COPYRIGHT 2003 ACS
AN 1994:450101 HCAPLUS
DN 121:50101
TI Blood-coagulation factor III analogs unable to activate factor VII
IN Ruf, Wolfram; Edgington, Thomas S.
PA Scripps Research Institute, USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

```
     PATENT NO.         KIND  DAT           APPLICATION NO.  DATE
     --------------     ----  --------      ---------------  --------
PI   WO 9407515          A1   19940414      WO 1993-US9570   19931006
        W:  CA, JP
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI US 1992-957985          19921006

=> dis his

     (FILE 'HOME' ENTERED AT 19:43:17 ON 07 MAR 2003)

     FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS,
     NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 19:43:26 ON 07 MAR 2003
L1            59 S FACTOR VII ACTIVATING AND (PROTEASE OR PROTEOLYTIC)
L2            24 DUP REM L1 (35 DUPLICATES REMOVED)

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    59.20      59.41

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:58:11 ON 07 MAR 2003
```